PLoS Pathogens (May 2020)

Emergence of prions selectively resistant to combination drug therapy.

  • Cassandra M Burke,
  • Kenneth M K Mark,
  • Judit Kun,
  • Kathryn S Beauchemin,
  • Surachai Supattapone

DOI
https://doi.org/10.1371/journal.ppat.1008581
Journal volume & issue
Vol. 16, no. 5
p. e1008581

Abstract

Read online

Prions are unorthodox infectious agents that replicate by templating misfolded conformations of a host-encoded glycoprotein, collectively termed PrPSc. Prion diseases are invariably fatal and currently incurable, but oral drugs that can prolong incubation times in prion-infected mice have been developed. Here, we tested the efficacy of combination therapy with two such drugs, IND24 and Anle138b, in scrapie-infected mice. The results indicate that combination therapy was no more effective than either IND24 or Anle138b monotherapy in prolonging scrapie incubation times. Moreover, combination therapy induced the formation of a new prion strain that is specifically resistant to the combination regimen but susceptible to Anle138b. To our knowledge, this is the first report of a pathogen with specific resistance to combination therapy despite being susceptible to monotherapy. Our findings also suggest that combination therapy may be a less effective strategy for treating prions than conventional pathogens.